321 related articles for article (PubMed ID: 15013035)
1. Oxazolidinones: activity, mode of action, and mechanism of resistance.
Bozdogan B; Appelbaum PC
Int J Antimicrob Agents; 2004 Feb; 23(2):113-9. PubMed ID: 15013035
[TBL] [Abstract][Full Text] [Related]
2. Linezolid in vitro: mechanism and antibacterial spectrum.
Livermore DM
J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii9-16. PubMed ID: 12730138
[TBL] [Abstract][Full Text] [Related]
3. Oxazolidinones--a new class of broad-spectrum chemotherapeutics.
Sztanke K; Pasternak K; Sztanke M
Ann Univ Mariae Curie Sklodowska Med; 2004; 59(2):335-41. PubMed ID: 16146103
[TBL] [Abstract][Full Text] [Related]
4. [Linezolid, an agent from a new class of antibiotics].
Kuijper EJ; Schippers EF; Bernards AT
Ned Tijdschr Geneeskd; 2004 Aug; 148(32):1577-81. PubMed ID: 15382556
[TBL] [Abstract][Full Text] [Related]
5. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.
Ross JE; Anderegg TR; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 May; 52(1):53-8. PubMed ID: 15878443
[TBL] [Abstract][Full Text] [Related]
6. [Linezolid--novel antibiotic for the treatment of gram-positive bacterial infections].
Jankowski A; Stefanik W
Wiad Lek; 2006; 59(9-10):727-31. PubMed ID: 17338140
[TBL] [Abstract][Full Text] [Related]
7. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
Anderegg TR; Sader HS; Fritsche TR; Ross JE; Jones RN
Int J Antimicrob Agents; 2005 Jul; 26(1):13-21. PubMed ID: 15967640
[TBL] [Abstract][Full Text] [Related]
8. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center.
Kloss P; Xiong L; Shinabarger DL; Mankin AS
J Mol Biol; 1999 Nov; 294(1):93-101. PubMed ID: 10556031
[TBL] [Abstract][Full Text] [Related]
9. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA.
Meka VG; Pillai SK; Sakoulas G; Wennersten C; Venkataraman L; DeGirolami PC; Eliopoulos GM; Moellering RC; Gold HS
J Infect Dis; 2004 Jul; 190(2):311-7. PubMed ID: 15216466
[TBL] [Abstract][Full Text] [Related]
10. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.
Johnson AP; Mushtaq S; Warner M; Livermore DM
Int J Antimicrob Agents; 2004 Oct; 24(4):315-9. PubMed ID: 15380254
[TBL] [Abstract][Full Text] [Related]
11. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.
Livermore DM; Mushtaq S; Warner M; Woodford N
J Antimicrob Chemother; 2009 Apr; 63(4):713-5. PubMed ID: 19164418
[TBL] [Abstract][Full Text] [Related]
12. Protected nucleotide G2608 in 23S rRNA confers resistance to oxazolidinones in E. coli.
Xu J; Golshani A; Aoki H; Remme J; Chosay J; Shinabarger DL; Ganoza MC
Biochem Biophys Res Commun; 2005 Mar; 328(2):471-6. PubMed ID: 15694371
[TBL] [Abstract][Full Text] [Related]
13. Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage.
Bonora MG; Solbiati M; Stepan E; Zorzi A; Luzzani A; Catania MR; Fontana R
J Clin Microbiol; 2006 Mar; 44(3):1153-5. PubMed ID: 16517918
[TBL] [Abstract][Full Text] [Related]
14. Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.
Jones RN; Moet GJ; Sader HS; Fritsche TR
J Antimicrob Chemother; 2004 May; 53(5):804-7. PubMed ID: 15056649
[TBL] [Abstract][Full Text] [Related]
15. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria.
Leach KL; Swaney SM; Colca JR; McDonald WG; Blinn JR; Thomasco LM; Gadwood RC; Shinabarger D; Xiong L; Mankin AS
Mol Cell; 2007 May; 26(3):393-402. PubMed ID: 17499045
[TBL] [Abstract][Full Text] [Related]
16. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.
Jones RN; Ross JE; Fritsche TR; Sader HS
J Antimicrob Chemother; 2006 Feb; 57(2):279-87. PubMed ID: 16326811
[TBL] [Abstract][Full Text] [Related]
17. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype.
Pillai SK; Sakoulas G; Wennersten C; Eliopoulos GM; Moellering RC; Ferraro MJ; Gold HS
J Infect Dis; 2002 Dec; 186(11):1603-7. PubMed ID: 12447736
[TBL] [Abstract][Full Text] [Related]
18. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Oct; 59(2):199-209. PubMed ID: 17908617
[TBL] [Abstract][Full Text] [Related]
19. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
Ross JE; Fritsche TR; Sader HS; Jones RN
Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
[TBL] [Abstract][Full Text] [Related]
20. New drugs for Gram-positive uropathogens.
Wagenlehner FM; Naber KG
Int J Antimicrob Agents; 2004 Sep; 24 Suppl 1():S39-43. PubMed ID: 15364305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
